Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies

Clinical Cancer Research

Volumn 11, Issue 19 II, 2005, Pages

  DeNardo, Gerald L ^a,b   Tobin, Evan ^a   Chan, Kaylund ^a   Bradt, Bonnie M ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; HLA ANTIBODY; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; ONCOLYM; RITUXIMAB; YTTRIUM 90;

CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DOSIMETRY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOMA CELL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RAJI CELL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORING AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HLA-DR ANTIGENS; HUMANS; LYMPHOMA; LYMPHOMA, LARGE-CELL; MICE; MICROSCOPY, FLUORESCENCE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TIME FACTORS; TREATMENT OUTCOME; TRYPAN BLUE; YTTRIUM RADIOISOTOPES;

EID: 26444558145     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1004-0008     Document Type: Conference Paper

References (24)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
2. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
3. Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin Oncol 2002;29:81-6.
4. Hegde U, White T, Stetler-Stevenson M, et al. Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-Cell lymphoma and chronic lymphocytic leukemia. Blood 2002;100:358a.
5. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28.
6. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246-56.
7. Leveille C, Cataigne JG, Charron D, Al-Daccak R. MHC class II isotype-specific signaling complex on human B cells. Eur J Immunol 2002;32:2282-91.
8. Leveille C, Al-Daccak R, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol 1999;29:65-74.
9. Szollosi J, Horejsi V, Bene L, Angelisova P, Damjanovich S. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol 1996;157:2939-46.
10. Liu C, DeNardo GL, Tobin E, DeNardo SJ. Anti-lymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. Cancer Biother Radiopharm 2004;19:545-61.
11. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26-30.
12. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830-40.
13. Hellstrom I, Beaumier PL, Hellstrom KE. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci U S A 1986;83:7059-63.
14. Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med 1998;39:2105-10.
15. Kukis DL, DeNardo GL, DeNardo SJ, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 1995;55:878-84.
16. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York: Society of Nuclear Medicine; 1988.
17. Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiological studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 1997;80:2519-28.
18. Siegel JA, Stabin MG. Absorbed fractions for electrons and β particles in spheres of various sizes. J Nucl Med 1994;35:152-6.
19. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003;9:3991-4S.
20. Nabhan C, Tallman M, Riley M, et al. Phase I study of rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2001;98:365a.
21. Faderl S, Thomas DA, O'Brien S, et al. An exploratory study of the combination of monoclonal antibodies Campath-1H and rituximab in the treatment of CD52-and CD20-positive chronic lymphoid disorders. Blood 2001;98:365a.
22. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PL. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906-12.
23. Igarashi T, Ohtsu T, Fujii H, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001;73:213-21.
24. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68.